To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.
Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.
The Quirem team will attend EANM in Barcelona from 12-16 October 2019.
SIRT in three steps
Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:
News and events
In their study, Smits et al. showed that QuiremScout® is a superior predictor of intrahepatic dose distribution compared to Tech-99m-MAA. The results of their study were published online on the 9th of August 2019 in
Deventer, August 7, 2019 – Today a first clinical QuiremScout® patient procedure took place with radioactive holmium-166 microspheres that were activated at the NRG reactor in Petten, the Netherlands. QuiremScout® is an innovative product for
On July 31, Quirem Medical received with great pleasure Mr. Zhang Guosheng – the Economic & Commercial Counsellor from the Embassy of the People’s Republic of China. The CEO of Quirem Medical, Jan Sigger, and the
What our customers say